Search results for "PLACEBO"

showing 10 items of 704 documents

Moving from the Oslerian paradigm to the postgenomic era: Are asthma and COPD outdated terms?

2016

In the majority of cases, asthma and chronic obstructive pulmonary disease (COPD) are two clearly distinct disease entities. However, in some patients there may be significant overlap between the two conditions. This constitutes an important area of concern because these patients are generally excluded from randomised controlled trials (mostly because of smoking history in the case of asthma or because of significant bronchodilator reversibility in the case of COPD). As a result, their pathobiology, prognosis and response to therapy are largely unknown. This may lead to suboptimal management and can limit the development of more personalised therapeutic options. Emerging genetic and molecul…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPlacebo-controlled studyAlternative medicinePHENOTYPESAIRWAY DISEASEDiseasePLACEBO-CONTROLLED TRIALOBSTRUCTIVE PULMONARY-DISEASETHERAPYCOPD MechanismsDOUBLE-BLINDPulmonary Disease Chronic ObstructiveAsthma; COPD MechanismsTerminology as TopicmedicineHumansDiseasePrecision MedicineIntensive care medicineINDEXAsthmaCLUSTER-ANALYSISCOPDbusiness.industrySystems Biologymedicine.diseaseAsthmaLUNG-FUNCTIONSystems medicineEXACERBATIONSPhenotypePhysical therapyHealth educationPersonalized medicinebusinessThorax
researchProduct

Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with …

2020

Reynold A Panettieri Jr,1 Tobias Welte,2 Kartik V Shenoy,3 Stephanie Korn,4 Margret Jandl,5 Edward M Kerwin,6 Rosa Feijoo,7 Peter Barker,8 Richard F Olsson,9 Ubaldo J Martin8 On behalf of the SOLANA Study Investigators1Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Philadelphia, PA, USA; 2Department of Respiratory Medicine, Member of the German Center of Lung Research, Medizinische Hochschule Hannover, Hannover, Germany; 3Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; 4Pulmonary Department, Universitätsmedizin Mainz, Langenbeckstr, Mainz, Germany; 5Hamburger Institut Für Th…

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtybenralizumabPlacebolaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineClinical endpointJournal of Asthma and AllergyImmunology and AllergyMedicinePlethysmographLung volumesOriginal Researchbusiness.industryBenralizumabanti–IL-5RαConfidence intervalchemistryAsthma Control Questionnairerandomized controlled trialinterleukin-5businesseosinophilicJournal of Asthma and Allergy
researchProduct

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study…

2020

BACKGROUND: Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.METHODS: In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centres worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [&l…

RESISTANT STARCHPlacebo-controlled study030204 cardiovascular system & hematology0302 clinical medicineLife Tables030212 general & internal medicine11 Medical and Health Sciencesmedia_commonRISKAspirineducation.field_of_studyAnti-Inflammatory Agents Non-SteroidalLOW-DOSE ASPIRINGeneral MedicineLynch syndrome3. Good healthIntention to Treat AnalysisAnti-Inflammatory Agents Non-Steroidal/adverse effectsmedicine.drugCHEMOPREVENTIONmedicine.medical_specialtyHeterozygote3122 CancersPopulationNEOPLASIAAspirin/adverse effectsPlaceboCAPP2 InvestigatorsMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal medicineGeneral & Internal MedicineColorectal Neoplasms Hereditary Nonpolyposis/geneticsBENEFITSmedicinemedia_common.cataloged_instanceHumansEuropean unioneducationProportional Hazards ModelsIntention-to-treat analysisCancer preventionAspirinbusiness.industryMORTALITY3126 Surgery anesthesiology intensive care radiologymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisbusinessFollow-Up Studies
researchProduct

Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled…

2017

Dysbalance in gut microbiota has been linked to increased microbial translocation, leading to chronic inflammation in HIV-patients, even under effective HAART. Moreover, microbial translocation is associated with insufficient reconstitution of CD4+T cells, and contributes to the pathogenesis of immunologic non-response. In a double-blind, randomised, placebo-controlled trial, we recently showed that, compared to placebo, 12 weeks treatment with probiotic Saccharomyces boulardii significantly reduced plasma levels of bacterial translocation (Lipopolysaccharide-binding protein or LBP) and systemic inflammation (IL-6) in 44 HIV virologically suppressed patients, half of whom (n = 22) had immun…

RNA virusesMale0301 basic medicinePlacebo-controlled studylcsh:MedicineHIV InfectionsGut floraPathology and Laboratory MedicineSystemic inflammationlaw.inventionPlacebosProbiotic0302 clinical medicineImmunodeficiency ViruseslawMedicine and Health SciencesMedicinelcsh:ScienceImmune ResponseMultidisciplinarybiologyMicrobiotaGenomicsMiddle AgedProbiòticsBacterial PathogensIntestinesSaccharomyces boulardiiMedical MicrobiologyViral PathogensVirusesFemale030211 gastroenterology & hepatologyPathogensmedicine.symptomResearch ArticleSaccharomyces boulardiiAdultImmunologyMicrobial GenomicsMicrobiologySaccharomyces03 medical and health sciencesSigns and SymptomsImmune systemDouble-Blind MethodDiagnostic MedicineRetrovirusesGeneticsVIH (Virus)HumansMicrobiomeMicrobial PathogensInflammationClostridiumBacteriabusiness.industryProbioticsGut BacteriaLentivirusLachnospiraceaelcsh:ROrganismsFungiBiology and Life SciencesHIVbiology.organism_classificationYeast030104 developmental biologyImmunologylcsh:QMicrobiomebusinessPLoS ONE
researchProduct

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal

2011

OBJECTIVE To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. RESEARCH DESIGN AND METHODS The 3,366 DREAM subjects at trial end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral glucose tolerance test. Glycemic status was analyzed for the trial plus washout period and for the washout period alone. RESULTS Following median (interquartile range) 71 (63–86) days drug withdrawal, overall glycemic status remained modestly improved in t…

RamiprilAdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyPlaceboRosiglitazone03 medical and health sciencesDrug withdrawal0302 clinical medicineRamiprilInterquartile rangeInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsGlycemicOriginal ResearchAdvanced and Specialized Nursingbusiness.industryIncidence (epidemiology)IncidenceClinical Care/Education/Nutrition/Psychosocial ResearchMiddle Agedmedicine.disease3. Good healthSurgerySubstance Withdrawal SyndromeTreatment OutcomeDiabetes Mellitus Type 2FemaleThiazolidinedionesRosiglitazonebusinessmedicine.drugFollow-Up StudiesDiabetes Care
researchProduct

Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial

2022

Abstract Aims The role of diuretics in patients with intermediate-risk pulmonary embolism (PE) is controversial. In this multicentre, double-blind trial, we randomly assigned normotensive patients with intermediate-risk PE to receive either a single 80 mg bolus of furosemide or a placebo. Methods and results Eligible patients had at least a simplified PE Severity Index (sPESI) ≥1 with right ventricular dysfunction. The primary efficacy endpoint assessed 24 h after randomization included (i) absence of oligo-anuria and (ii) normalization of all sPESI items. Safety outcomes were worsening renal function and major adverse outcomes at 48 hours defined by death, cardiac arrest, mechanical ventil…

Randomizationmedicine.medical_treatmentVentricular Dysfunction Right[SDV]Life Sciences [q-bio]Critical Care and Intensive Care MedicinePlacebolaw.inventionRandomized controlled trialDouble-Blind MethodlawFurosemidemedicineHumansDiureticsbusiness.industryFurosemideGeneral Medicinemedicine.diseasePulmonary embolismBlood pressureTreatment OutcomeAnesthesiaAcute DiseaseDiureticBolus (digestion)Cardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct

Responsiveness to change and reliability of measurement of radiographic joint space width in osteoarthritis of the knee: a systematic review

2011

Import JabRef | WosArea Orthopedics; Rheumatology; International audience; Objective: The goal of this systematic review was to report the responsiveness to change and reliability of conventional radiographic joint space width (JSW) measurement. Method: We searched the PubMed and Embase databases using the following search criteria: [osteoarthritis (OA) (MeSH)] AND (knee) AND (X-ray OR radiography OR diagnostic imaging OR radiology OR disease progression) AND (joint space OR JSW or disease progression). We assessed responsiveness by calculating the standardized response mean (SRM). We assessed reliability using intra- and inter-reader intra-class correlation (ICC) and coefficient of variati…

Research designmedicine.medical_specialtyRadiographKnee JointRadiographyCoefficient of variationBiomedical EngineeringOsteoarthritisARTHROSCOPIC EVALUATIONCHONDROITINS 4Knee JointPLACEBO-CONTROLLED TRIALArticleX-ray03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineFIXED-FLEXIONRheumatologyStandardized response meanmedicineHumansFluoroscopyOrthopedics and Sports MedicineReliability (statistics)Observer Variation030203 arthritis & rheumatology030222 orthopedicsSTANDING ANTEROPOSTERIORmedicine.diagnostic_testbusiness.industry[SCCO.NEUR] Cognitive science/NeuroscienceDISEASE PROGRESSIONReproducibility of ResultsResponsivenessOsteoarthritis Kneemedicine.diseaseReliabilityConfidence interval3. Good healthGLUCOSAMINE SULFATEResearch DesignFluoroscopyPhysical therapyKnee osteoarthritisSENSITIVITYbusinessMEDIAL TIBIAL PLATEAU
researchProduct

Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial)

2015

TPS789 Background: Treatment of metastatic colorectal cancer (mCRC) has improved due to the introduction of more active chemotherapies (CT) and novel targeted agents that have significantly increased response rate (RR), progression free survival (PFS) and overall survival (OS). Recently, CORRECT and CONCUR trials have demonstrated both activity and efficacy of regorafenib, a small multi-kinase inhibitor, as monotherapy in pretreated mCRC. The wide range of action of regorafenib makes it an ideal candidate for monotherapy in earlier disease treatment lines in which different pathways could be involved in the acquisition of resistance. To improve long term efficacy of first line therapy seve…

Response rate (survey)OncologyCancer Researchmedicine.medical_specialtybusiness.industryColorectal cancerWild typeHematologyPharmacologyPlacebomedicine.diseasechemistry.chemical_compoundOncologyMaintenance therapychemistryRegorafenibInternal medicineOverall survivalMedicineProgression-free survivalbusinessAnnals of Oncology
researchProduct

Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization

2021

Abstract Background Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality. Objectives This study assessed DCD safety and effectiveness in LER for PAD. Methods VOYAGER PAD (Vascular Outcomes Study of ASA [acetylsalicylic acid] Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) randomized patients with PAD who underwent LER to rivaroxaban or placebo. The primary VOYAGER PAD study efficacy and safety outcomes were composite cardiovascular and limb events and Thrombolysis In Myocardial Infarction major bleeding. For prespe…

Rivaroxabanmedicine.medical_specialtyProportional hazards modelbusiness.industrymedicine.medical_treatmentThrombolysisRevascularizationPlacebomedicine.diseasechemistry.chemical_compoundPaclitaxelchemistryInternal medicinemedicineCardiologyMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugJournal of the American College of Cardiology
researchProduct

Assessment of the capacity of a pyrophosphate-based mouth rinse to inhibit the formation of supragingival dental calculus. a randomized double-blind …

2019

Background This study aimed to analyze the efficacy of an anti-calculus mouth rinse and its possible adverse effects on the mucosa and teeth. Material and Methods This randomized double-blind placebo-controlled clinical trial included 40 patients with treated and managed periodontal disease, all with a history of rapid calculus formation. Patients used a pyrophosphate-based test mouth rinse (B) or a placebo (A). A range of parameters were measured for: saliva (saliva flow, pH and chemical composition); calculus (Volpe-Manhold [V-M] index, weight, and volume); adverse effects on mucosa and teeth; and the patients’ subjective perceptive of mouth rinse efficacy. Results The test mouth rinse B …

SalivaMouthwashesPlacebolaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind Methodstomatognathic systemRandomized controlled triallawDentifriceCalculusHumansMedicineDental CalculusAdverse effectGeneral DentistryDentifricesOral Medicine and Pathologybusiness.industryResearchCalculus (dental)030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDiphosphatesstomatognathic diseasesOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASUreaUric acidSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct